Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine/threonine-protein kinase ATR is a member of the PIKK family and plays a crucial role in the DNA damage response. It acts as a sensor of DNA damage, particularly single-stranded DNA, and activates cell cycle checkpoints by phosphorylating key downstream targets like CHK1, RAD17/RAD9 complex members, and BRCA1. ATR forms a complex with ATRIP, which is essential for its recruitment and activation at sites of DNA damage. ATR is involved in responses to various forms of genotoxic stress, including ionizing radiation, UV radiation, and stalled replication forks. ATR inhibitors are under development as cancer therapeutics.
ATR kinase inhibitors prevent DNA damage repair and cell cycle arrest in cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine/threonine-protein kinase ATR (ATR).